CL2012000565A1 - Procedimiento de preparacion del acido (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595). - Google Patents

Procedimiento de preparacion del acido (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595).

Info

Publication number
CL2012000565A1
CL2012000565A1 CL2012000565A CL2012000565A CL2012000565A1 CL 2012000565 A1 CL2012000565 A1 CL 2012000565A1 CL 2012000565 A CL2012000565 A CL 2012000565A CL 2012000565 A CL2012000565 A CL 2012000565A CL 2012000565 A1 CL2012000565 A1 CL 2012000565A1
Authority
CL
Chile
Prior art keywords
sns
naphthyridine
pyrrolidinyl
methylamino
thiazolyl
Prior art date
Application number
CL2012000565A
Other languages
English (en)
Inventor
Ahmad Sudhakar Anantha Jacobs Jeff Ritchie Sean Cheng Hengqin Hashash
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of CL2012000565A1 publication Critical patent/CL2012000565A1/es
Priority to CL2014000446A priority Critical patent/CL2014000446A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

UN PROCEDIMIENTO PARA PREPARAR UNA SUSTANCIA SNS-595, QUE COMPRENDE: (A) HACER REACCIONAR EL COMPUESTO 3 CON UNA PRIMERA BASE ACUOSA SEGUIDO POR NEUTRALIZACIÓN PARA OBTENER UN HIDRATO DE SNS-595 PRIMARIO; DESHIDRATAR EL HIDRATO DE SNS-595 PRIMARIO DEL PASO (A) Y HACER REACCIONAR EL PRODUCTO DESHIDRATADO CON UNA SEGUNDA BASE ACUOSA SEGUIDO POR LA NEUTRALIZACIÓN PARA OBTENER UN HIDRATO DE SNS-595 SECUNDARIO; Y DESHIDRATAR EL HIDRATO DE SNS-595 SECUNDARIO OBTENIDO EN EL PASO (C) PARA OBTENER LA SUSTANCIA DE SNS-595.
CL2012000565A 2009-09-04 2012-03-02 Procedimiento de preparacion del acido (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595). CL2012000565A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2014000446A CL2014000446A1 (es) 2009-09-04 2014-02-25 Composicion que comprende a la sustancia acida pura (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-metilamino-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595) y a uno o mas de otros compuestos (divisional de la solicitud 565-2012).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24016109P 2009-09-04 2009-09-04

Publications (1)

Publication Number Publication Date
CL2012000565A1 true CL2012000565A1 (es) 2012-12-07

Family

ID=42990341

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000565A CL2012000565A1 (es) 2009-09-04 2012-03-02 Procedimiento de preparacion del acido (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595).

Country Status (26)

Country Link
US (5) US8586601B2 (es)
EP (2) EP2674431A1 (es)
JP (3) JP6339315B2 (es)
KR (3) KR20170102568A (es)
CN (2) CN102596948B (es)
AU (1) AU2010289337B2 (es)
BR (1) BR112012004916A2 (es)
CA (2) CA3002440A1 (es)
CL (1) CL2012000565A1 (es)
CO (1) CO6511211A2 (es)
DK (1) DK2473507T3 (es)
EA (2) EA201270377A1 (es)
ES (1) ES2462502T3 (es)
HK (1) HK1172032A1 (es)
HR (1) HRP20140372T1 (es)
IL (3) IL218404A (es)
MX (1) MX2012002573A (es)
NZ (2) NZ598467A (es)
PH (1) PH12014500714B1 (es)
PL (1) PL2473507T3 (es)
PT (1) PT2473507E (es)
SG (3) SG2014013163A (es)
TW (2) TWI519535B (es)
UA (1) UA110465C2 (es)
WO (1) WO2011028979A1 (es)
ZA (1) ZA201201469B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2295056T3 (pl) * 2004-03-15 2016-07-29 Sunesis Pharmaceuticals Inc Zastosowanie SNS-595 do leczenia białaczki
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
MX2010004350A (es) 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
WO2009075841A2 (en) 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
AU2009335159B2 (en) 2008-12-31 2015-07-23 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
SK281341B6 (sk) 1994-06-14 2001-02-12 Dainippon Pharmaceutical Co., Ltd. Deriváty pyridónkarboxylovej kyseliny alebo jej farmaceuticky prijateľných solí, spôsob ich prípravy a farmakologické prostriedky ich obsahujúce
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
JP4294121B2 (ja) * 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
JP4178783B2 (ja) 2001-10-19 2008-11-12 三菱化学株式会社 光学記録媒体
PL2295056T3 (pl) 2004-03-15 2016-07-29 Sunesis Pharmaceuticals Inc Zastosowanie SNS-595 do leczenia białaczki
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
HUE026693T2 (hu) * 2006-08-02 2016-07-28 Sunesis Pharmaceuticals Inc (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére
MX2010004350A (es) * 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
WO2009075841A2 (en) * 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
AU2009335159B2 (en) 2008-12-31 2015-07-23 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
AU2010217796B2 (en) 2009-02-27 2015-04-30 Sunesis Pharmaceuticals, Inc. Methods of using SNS-595 for treatment of cancer subjects with reduced BRCA2 activity
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
US20190084978A1 (en) 2019-03-21
IL218404A (en) 2015-07-30
ES2462502T3 (es) 2014-05-23
DK2473507T3 (da) 2014-04-22
EA201400683A1 (ru) 2015-05-29
IL218404A0 (en) 2012-04-30
PL2473507T3 (pl) 2014-08-29
PH12014500714A1 (en) 2015-09-07
UA110465C2 (en) 2016-01-12
US9469635B2 (en) 2016-10-18
IL237724A (en) 2016-10-31
SG2014013163A (en) 2014-09-26
HRP20140372T1 (hr) 2014-06-20
CN102596948B (zh) 2015-07-22
US20110082169A1 (en) 2011-04-07
JP2013503899A (ja) 2013-02-04
WO2011028979A1 (en) 2011-03-10
KR101811763B1 (ko) 2017-12-22
US9969730B2 (en) 2018-05-15
JP6339315B2 (ja) 2018-06-06
IL247929B (en) 2018-01-31
CN104177359B (zh) 2018-06-01
KR20170102568A (ko) 2017-09-11
AU2010289337A1 (en) 2012-03-22
NZ598467A (en) 2014-04-30
EP2473507B1 (en) 2014-03-19
AU2010289337B2 (en) 2014-10-30
PT2473507E (pt) 2014-05-23
US20110086876A1 (en) 2011-04-14
SG10201808097QA (en) 2018-10-30
JP2018127457A (ja) 2018-08-16
CN102596948A (zh) 2012-07-18
EA201270377A1 (ru) 2013-01-30
PH12014500714B1 (en) 2015-09-07
US8138202B2 (en) 2012-03-20
ZA201201469B (en) 2013-05-29
NZ623780A (en) 2015-10-30
EP2674431A1 (en) 2013-12-18
SG178956A1 (en) 2012-04-27
CN104177359A (zh) 2014-12-03
CO6511211A2 (es) 2012-08-31
US20170226104A1 (en) 2017-08-10
TWI615391B (zh) 2018-02-21
TWI519535B (zh) 2016-02-01
EP2473507A1 (en) 2012-07-11
HK1172032A1 (en) 2013-04-12
CA3002440A1 (en) 2011-03-10
US20140275547A1 (en) 2014-09-18
KR20180112103A (ko) 2018-10-11
JP2016104769A (ja) 2016-06-09
TW201504240A (zh) 2015-02-01
US8586601B2 (en) 2013-11-19
KR20120078711A (ko) 2012-07-10
BR112012004916A2 (pt) 2017-07-04
TW201114767A (en) 2011-05-01
CA2772291A1 (en) 2011-03-10
MX2012002573A (es) 2012-04-10

Similar Documents

Publication Publication Date Title
CL2012000565A1 (es) Procedimiento de preparacion del acido (+)-1,4-dihidro-7-[(3s, 4s)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxilico (sns-595).
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
IN2014MN02106A (es)
MY174629A (en) Manufacture of 2-(5-bromo-4(4-cyclopropylnaphalen-1-yl)- 4h-1,2,4-triazol-3-ylthio)acetic acid
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
NI201200140A (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
MY171207A (en) Novel process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
MX2009003313A (es) Acidos quinolona carboxilicos, derivados de los mismos, procesos para su preparacion y su uso como agentes antibacterianos.
CL2013000589A1 (es) Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico.
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
NZ593763A (en) Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
MX2009007413A (es) Acidos quinolona carboxilicos, derivados de los mismos, y metodos de fabricacion y uso de los mismos.
MX362691B (es) Proceso para preparar cloruros de 4-[[(benzoil)amino]sulfonil]benz oílo y preparación de acilsulfamoilbenzamidas.
BR112012017485A2 (pt) derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído
BR112012017447A2 (pt) derivados de ácidos carboxílicos heterocíclicos tendo um anel oxazolopirimidina 2,5-substituído
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
BR112016022437A2 (pt) Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
WO2015027137A8 (en) Improved synthesis of capuramycin and its analogues
BR112012017240A2 (pt) derivados do ácido heterocíclico carboxílico tendo o anel de 2,5,7-oxazolopirimidina susbtituído